Shield Therapeutics plc
Shield Therapeutics plc
- Market cap
- $150.91M
Your view on SHIEF
Overview
What the company does, where it operates, and who runs it.
About Shield Therapeutics plc
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Anders Lundstrom
- Headquarters
- Northern Design Centre, Gateshead, GB
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Anders Lundstrom
- Headquarters
- Northern Design Centre, Gateshead, GB
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults.
It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Shield Therapeutics plc. Starting points for Shield Therapeutics plc: EPS -$0.0097, beta 1.96 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Shield Therapeutics plc. Shield Therapeutics plc does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Shield Therapeutics plc. Trailing twelve-month EPS for Shield Therapeutics plc stands at -$0.0097. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|
| Average estimate | −$0.00 | $0.00 |
| Lowest estimate | −$0.01 | $0.00 |
| Highest estimate | −$0.00 | $0.00 |
| Number of analysts | 1 | 1 |
| A year ago | −$0.021 | — |
| Growth vs a year ago | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|
| Average estimate | $44.78M | $53.47M |
| Lowest estimate | $40.44M | $40.29M |
| Highest estimate | $53.02M | $78.33M |
| Number of analysts | 3 | 3 |
| A year ago | $50.81M | — |
| Growth vs a year ago | −11.9% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Shield Therapeutics plc. Shield Therapeutics plc has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| BIOYFBioSyent Inc. | Healthcare | Medical - Pharmaceuticals | $130.2M | ||
| GGBXFGreen Growth Brands Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $2,061 | ||
| GRUSFGrown Rogue International Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $89.8M | ||
| HLTRFHLS Therapeutics Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $105.1M | ||
| KNTPFKintor Pharmaceutical Limited | Healthcare | Biotechnology | $184.0M | ||
| LOVFFCannara Biotech Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $125.5M | ||
| ORXOFOrexo AB (publ) | Healthcare | Medical - Pharmaceuticals | $111.5M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| CHALFChalice Brands Ltd. | Healthcare | OTC | $6,660 | ||
| CHHEChina Health Industries Holdings, Inc. | Healthcare | OTC | $6,554 | ||
| CHIZFChina Traditional Chinese Medicine Holdings Co. Limited | Healthcare | OTC | $1.4B | ||
| CHOOFChoom Holdings Inc. | Healthcare | OTC | $4,670 | ||
| CHSYFChina Medical System Holdings Limited | Healthcare | OTC | $3.3B | ||
| CL.CNCresco Labs Inc. | Healthcare | CNQ | $565.2M | ||
| CLC.CNChristina Lake Cannabis Corp. | Healthcare | CNQ | $9.9M | ||
| CLCFFChristina Lake Cannabis Corp. | Healthcare | OTC | $6.2M | ||
| CLVRClever Leaves Holdings Inc. | Healthcare | OTC | $702 | ||
| CNFHFCanaFarma Hemp Products Corp. | Healthcare | OTC | $19,561 | ||
| CNGGFCann Group Limited | Healthcare | OTC | $4.4M | ||
| CNNACann American Corp. | Healthcare | OTC | $1.1M | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Shield Therapeutics plc. Coverage tracks Shield Therapeutics plc within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Shield Therapeutics plc.